調査レポート | • レポートコード：GIR-2104Z09063 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥494,160 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥741,240 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥988,320 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、黒色腫治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。黒色腫治療薬の種類別市場規模（化学療法、免疫療法、標的療法）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・黒色腫治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Amgen、Bristol-Myers Squibb、Roche、Genentech、Janssen Biotech、Novartis、Pfizer、Sanofi、Takeda Pharma、Teva Pharma ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：化学療法、免疫療法、標的療法 ・用途別分析2016年-2026年：病院、診療所、その他 ・黒色腫治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・黒色腫治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・黒色腫治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・黒色腫治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・黒色腫治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Melanoma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Melanoma Drugs size is estimated to be USD 3424.2 million in 2025 from USD 2216.7 million in 2019, with a change XX% between 2019 and 2020. The global Melanoma Drugs market size is expected to grow at a CAGR of 11.5% for the next five years.
Market segmentation
Melanoma Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chemotherapy
Immunotherapy
Targeted Therapy
Market segment by Application, can be divided into
Hospitals
Clinics
Others
Market segment by players, this report covers
Amgen
Bristol-Myers Squibb
Roche
Genentech
Janssen Biotech
Novartis
Pfizer
Sanofi
Takeda Pharma
Teva Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Melanoma Drugs
1.2 Classification of Melanoma Drugs by Type
1.2.1 Overview: Global Melanoma Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Melanoma Drugs Revenue Market Share by Type in 2020
1.2.3 Chemotherapy
1.2.4 Immunotherapy
1.2.5 Targeted Therapy
1.3 Global Melanoma Drugs Market by Application
1.3.1 Overview: Global Melanoma Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Melanoma Drugs Market Size & Forecast
1.5 Global Melanoma Drugs Market Size and Forecast by Region
1.5.1 Global Melanoma Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Melanoma Drugs Market Size by Region, (2016-2021)
1.5.3 North America Melanoma Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Melanoma Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Melanoma Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Melanoma Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Melanoma Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Melanoma Drugs Market Drivers
1.6.2 Melanoma Drugs Market Restraints
1.6.3 Melanoma Drugs Trends Analysis
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Melanoma Drugs Product and Solutions
2.1.4 Amgen Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Amgen Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Melanoma Drugs Product and Solutions
2.2.4 Bristol-Myers Squibb Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Melanoma Drugs Product and Solutions
2.3.4 Roche Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Roche Recent Developments and Future Plans
2.4 Genentech
2.4.1 Genentech Details
2.4.2 Genentech Major Business
2.4.3 Genentech Melanoma Drugs Product and Solutions
2.4.4 Genentech Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Genentech Recent Developments and Future Plans
2.5 Janssen Biotech
2.5.1 Janssen Biotech Details
2.5.2 Janssen Biotech Major Business
2.5.3 Janssen Biotech Melanoma Drugs Product and Solutions
2.5.4 Janssen Biotech Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Janssen Biotech Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Melanoma Drugs Product and Solutions
2.6.4 Novartis Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Melanoma Drugs Product and Solutions
2.7.4 Pfizer Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Melanoma Drugs Product and Solutions
2.8.4 Sanofi Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Takeda Pharma
2.9.1 Takeda Pharma Details
2.9.2 Takeda Pharma Major Business
2.9.3 Takeda Pharma Melanoma Drugs Product and Solutions
2.9.4 Takeda Pharma Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Takeda Pharma Recent Developments and Future Plans
2.10 Teva Pharma
2.10.1 Teva Pharma Details
2.10.2 Teva Pharma Major Business
2.10.3 Teva Pharma Melanoma Drugs Product and Solutions
2.10.4 Teva Pharma Melanoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Teva Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Melanoma Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Melanoma Drugs Players Market Share
3.2.2 Top 10 Melanoma Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Melanoma Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Melanoma Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Melanoma Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Melanoma Drugs Revenue Market Share by Application (2016-2021)
5.2 Melanoma Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Melanoma Drugs Revenue by Type (2016-2026)
6.2 North America Melanoma Drugs Revenue by Application (2016-2026)
6.3 North America Melanoma Drugs Market Size by Country
6.3.1 North America Melanoma Drugs Revenue by Country (2016-2026)
6.3.2 United States Melanoma Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Melanoma Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Melanoma Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Melanoma Drugs Revenue by Type (2016-2026)
7.2 Europe Melanoma Drugs Revenue by Application (2016-2026)
7.3 Europe Melanoma Drugs Market Size by Country
7.3.1 Europe Melanoma Drugs Revenue by Country (2016-2026)
7.3.2 Germany Melanoma Drugs Market Size and Forecast (2016-2026)
7.3.3 France Melanoma Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Melanoma Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Melanoma Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Melanoma Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Melanoma Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Melanoma Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Melanoma Drugs Market Size by Region
8.3.1 Asia-Pacific Melanoma Drugs Revenue by Region (2016-2026)
8.3.2 China Melanoma Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Melanoma Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Melanoma Drugs Market Size and Forecast (2016-2026)
8.3.5 India Melanoma Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Melanoma Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Melanoma Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Melanoma Drugs Revenue by Type (2016-2026)
9.2 South America Melanoma Drugs Revenue by Application (2016-2026)
9.3 South America Melanoma Drugs Market Size by Country
9.3.1 South America Melanoma Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Melanoma Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Melanoma Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Melanoma Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Melanoma Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Melanoma Drugs Market Size by Country
10.3.1 Middle East & Africa Melanoma Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Melanoma Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Melanoma Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Melanoma Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Melanoma Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Melanoma Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Melanoma Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Melanoma Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Melanoma Drugs Revenue Market Share by Region (2021-2026)
Table 6. Amgen Corporate Information, Head Office, and Major Competitors
Table 7. Amgen Major Business
Table 8. Amgen Melanoma Drugs Product and Solutions
Table 9. Amgen Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Major Business
Table 12. Bristol-Myers Squibb Melanoma Drugs Product and Solutions
Table 13. Bristol-Myers Squibb Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Roche Corporate Information, Head Office, and Major Competitors
Table 15. Roche Major Business
Table 16. Roche Melanoma Drugs Product and Solutions
Table 17. Roche Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Genentech Corporate Information, Head Office, and Major Competitors
Table 19. Genentech Major Business
Table 20. Genentech Melanoma Drugs Product and Solutions
Table 21. Genentech Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Janssen Biotech Corporate Information, Head Office, and Major Competitors
Table 23. Janssen Biotech Major Business
Table 24. Janssen Biotech Melanoma Drugs Product and Solutions
Table 25. Janssen Biotech Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis Melanoma Drugs Product and Solutions
Table 29. Novartis Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Pfizer Corporate Information, Head Office, and Major Competitors
Table 31. Pfizer Major Business
Table 32. Pfizer Melanoma Drugs Product and Solutions
Table 33. Pfizer Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Melanoma Drugs Product and Solutions
Table 37. Sanofi Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Takeda Pharma Corporate Information, Head Office, and Major Competitors
Table 39. Takeda Pharma Major Business
Table 40. Takeda Pharma Melanoma Drugs Product and Solutions
Table 41. Takeda Pharma Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Teva Pharma Corporate Information, Head Office, and Major Competitors
Table 43. Teva Pharma Major Business
Table 44. Teva Pharma Melanoma Drugs Product and Solutions
Table 45. Teva Pharma Melanoma Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Melanoma Drugs Revenue (USD Million) by Players (2019-2021)
Table 47. Global Melanoma Drugs Revenue Share by Players (2019-2021)
Table 48. Breakdown of Melanoma Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Melanoma Drugs Players Head Office, Products and Services Provided
Table 50. Melanoma Drugs Mergers & Acquisitions in the Past Five Years
Table 51. Melanoma Drugs New Entrants and Expansion Plans
Table 52. Global Melanoma Drugs Revenue (USD Million) by Type (2016-2021)
Table 53. Global Melanoma Drugs Revenue Share by Type (2016-2021)
Table 54. Global Melanoma Drugs Revenue Forecast by Type (2021-2026)
Table 55. Global Melanoma Drugs Revenue by Application (2016-2021)
Table 56. Global Melanoma Drugs Revenue Forecast by Application (2021-2026)
Table 57. North America Melanoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Melanoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Melanoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Melanoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Melanoma Drugs Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Melanoma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Melanoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Melanoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Melanoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Melanoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Melanoma Drugs Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Melanoma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Melanoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Melanoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Melanoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Melanoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Melanoma Drugs Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Melanoma Drugs Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Melanoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Melanoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Melanoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Melanoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Melanoma Drugs Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Melanoma Drugs Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Melanoma Drugs Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Melanoma Drugs Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Melanoma Drugs Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Melanoma Drugs Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Melanoma Drugs Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Melanoma Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Melanoma Drugs Picture
Figure 2. Global Melanoma Drugs Revenue Market Share by Type in 2020
Figure 3. Chemotherapy
Figure 4. Immunotherapy
Figure 5. Targeted Therapy
Figure 6. Melanoma Drugs Revenue Market Share by Application in 2020
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Others Picture
Figure 10. Global Melanoma Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Melanoma Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Melanoma Drugs Revenue Market Share by Region (2016-2026)
Figure 13. Global Melanoma Drugs Revenue Market Share by Region in 2020
Figure 14. North America Melanoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Melanoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Melanoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Melanoma Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Melanoma Drugs Market Drivers
Figure 19. Melanoma Drugs Market Restraints
Figure 20. Melanoma Drugs Market Trends
Figure 21. Amgen Recent Developments and Future Plans
Figure 22. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 23. Roche Recent Developments and Future Plans
Figure 24. Genentech Recent Developments and Future Plans
Figure 25. Janssen Biotech Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Pfizer Recent Developments and Future Plans
Figure 28. Sanofi Recent Developments and Future Plans
Figure 29. Takeda Pharma Recent Developments and Future Plans
Figure 30. Teva Pharma Recent Developments and Future Plans
Figure 32. Global Melanoma Drugs Revenue Share by Players in 2020
Figure 33. Melanoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Melanoma Drugs Revenue Market Share in 2020
Figure 35. Global Top 10 Players Melanoma Drugs Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Melanoma Drugs Revenue Share by Type in 2020
Figure 38. Global Melanoma Drugs Market Share Forecast by Type (2021-2026)
Figure 39. Global Melanoma Drugs Revenue Share by Application in 2020
Figure 40. Global Melanoma Drugs Market Share Forecast by Application (2021-2026)
Figure 41. North America Melanoma Drugs Sales Market Share by Type (2016-2026)
Figure 42. North America Melanoma Drugs Sales Market Share by Application (2016-2026)
Figure 43. North America Melanoma Drugs Revenue Market Share by Country (2016-2026)
Figure 44. United States Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Melanoma Drugs Sales Market Share by Type (2016-2026)
Figure 48. Europe Melanoma Drugs Sales Market Share by Application (2016-2026)
Figure 49. Europe Melanoma Drugs Revenue Market Share by Country (2016-2026)
Figure 50. Germany Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Melanoma Drugs Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Melanoma Drugs Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Melanoma Drugs Revenue Market Share by Region (2016-2026)
Figure 58. China Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Melanoma Drugs Sales Market Share by Type (2016-2026)
Figure 65. South America Melanoma Drugs Sales Market Share by Application (2016-2026)
Figure 66. South America Melanoma Drugs Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Melanoma Drugs Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Melanoma Drugs Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Melanoma Drugs Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Melanoma Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界の黒色腫治療薬市場規模・現状・予測（2021年-2027年） Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of…- 世界の悪性黒色腫治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Malignant Melanoma Drugs Market The global Malignant Melanoma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the …
- 世界の黒色腫市場規模・現状・予測（2021年-2027年） Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are mo…
- 世界の黒色腫市場規模・現状・予測（2021年-2027年） Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are mo…
- 世界の黒色腫治療市場 2021：企業別、地域別、種類・用途別 The Melanoma Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulatio…